The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS ...

Partner presentations reinforce ability of proprietary AzymetricTM platform to develop clinically validated therapeutic antibodies <li ...

When Al Roker shared that he'd been diagnosed with prostate cancer in late September, he mentioned an eye-opening statistic: 1 in 9 men will be diagnosed in their lifetime, and for Black men that ...

Michael Hiroshi Johnson, M.D. Exercise can help you look buff, trim your waistline and boost heart health, but research suggests that physical activity may offer an additional benefit: better odds ...

Breast cancer is the most common cancer in women in the United States, except for skin cancers. It accounts for about 30% (or 1 in 3) of all new female cancers each year. The American Cancer Society's ...

Men with liver disease can also have a higher chance of developing benign male breast growth (gynecomastia) and also have an higher risk of developing breast cancer. Estrogen-related drugs were once ...

When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a good target for treating advanced prostate cancer. You might hear this new treatment called lutetium ...

If you have advanced prostate cancer, it means the cancer has moved to a part of your body outside your prostate gland. The bones are a common place for it to spread. The cancer may show up in ...

will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress taking place May 14 – May 17 in Munich, Germany. Iza-bren is being jointly developed by ...

Arthritis is identified as an independent risk factor for prostate cancer, with significant associations found in various analyses. The study utilized NHANES data and Mendelian randomization to ...

will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress taking place May 14 – May 17 in Munich, Germany. Iza-bren is being jointly developed by ...

Updated safety & efficacy in Locally Advanced or Metastatic Breast Cancer will be presented from a Ph1 clinical study evaluating iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based ...